dt2216
Small moleculeexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 25, 2021 (NCT04886622)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06964009 | Phase 1 | Sep 22, 2025 | American Society of Clinical Oncology, Department of Defense, Dialectic Therapeutics, Inc, Harvard University |
| NCT06620302 | Phase 1/Phase 2 (Phase 2) | Dec 20, 2024 | National Cancer Institute (NCI) |
| NCT04886622 | Phase 1 | Aug 25, 2021 | Dialectic Therapeutics, Dialectic Therapeutics, Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dialectic Therapeutics, Inc | For profit | 2 | 1 | 1 | 2021 |
| American Society of Clinical Oncology | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Department of Defense | Government | 1 | 0 | 1 | 2025 |
| Dialectic Therapeutics | For profit | 1 | 0 | 1 | 2021 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2024 |
6 organizations
Page 1 / 1